Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab clinical trials

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

This study is for women aged 18-75 with a certain type of ovarian cancer. It tests a new treatment, ADP-A2M4CD8, alone or with nivolumab, to see how well it works and if it's safe.